Join us for this session focusing on AI applications in healthcare, including personalized treatment, drug discovery and development, and hospitals and clinics. Our discussions will cover approaches for building AI teams, setting up enterprise strategies, and partnering opportunities between healthcare, pharma, and technology experts. We'll also delve into the challenges of integrating AI solutions into the complex regulatory environment of life sciences while addressing ethical considerations and data privacy concerns.

Disclaimer: This event may be recorded, and your image and/or voice may be included in that recording. If you are uncomfortable, please be sure to turn off your webcam.  

Speaker Bios

Amanda Goltz, MPA, Director of Industry Partnerships for Stanford Medicine

Amanda Goltz, MPA, is the Director of Industry Partnerships for Stanford Medicine, driving the co-creation of novel digital health and technology solutions from research to implementation across both Stanford Health Care and the School of Medicine. Before joining Stanford, Amanda led two healthcare initiatives at Amazon – the Global Accelerator program for healthcare startups at Amazon Web Services (AWS), and the launching of Alexa Health and Wellness, the first-ever voice AI experiences for medication refills and management, home care plans, and COVID information. Amanda has held executive roles across the healthcare ecosystem, including at a pharma (BTG, now Boston Scientific), a payer (Aetna), an employer coalition (Pacific Business Group on Health), a state government (California Department of Health and Human Services), and two provider systems (MassGeneralBrigham and New York City Health and Hospital Corporation.) Amanda advises startup companies and VCs globally on innovation in the U.S. healthcare market, as well as technology companies' potential for driving change at scale in the healthcare industry. Amanda has a Master’s in Public Administration in Healthcare Finance and Policy from the Wagner School of Public Service at New York University and a BA from Columbia College of Columbia University.

Wasim Malik, PhD, Managing Partner at Iaso Ventures

Wasim is the Managing Partner at Iaso Ventures. He also serves on the clinical trial leadership at Massachusetts General Hospital and Harvard Medical School faculty. Previously, was the Chief Digital Strategist at Roivant Sciences, where he oversaw digital health investments and strategy. He sits on the board of the Epilepsy Foundation and is an advisor to the Broad Institute and Honeywell, among others. He received his PhD in electrical engineering from Oxford University, postdoctoral training in computational neuroscience at MIT, and finance education at Harvard Business School.

Stephanie Oestreich, PhD, Managing Director of the Investment Fund of the MMRF (Multiple Myeloma Research Foundation), Moderator

Stephanie is Managing Director of the Investment Fund of the MMRF and serves on the boards of the German American Business Council in Boston and the Harvard Kennedy School’s Women’s Network and is the chair of the McCloy Alumni Association. She is also on the faculty of MIT, a member of the Launchpad Venture Group, an advisor at grIP Venture Studio, to Biognosys (a Bruker company), Invitris, CART company CelineTx, Investment Fund Nekonal, and to the drug development and investment company OrangeGrove Bio and a member of the W20 Entrepreneurship task force, the official engagement group of the G20. Previously she was Chief Business Officer at Galecto (NASDAQ:GLTO), Vice President at cell therapy company Mnemo Therapeutics, a Venture Partner at RA Capital and Executive Vice President at Evotec (NASDAQ:EVO) where she built its North American investment arm and started an incubator with Samsara BioCapital. She also worked as International Business Leader at F. Hoffmann-La Roche Ltd. (ROG.SW), and for Novartis (NYSE:NVS) in Business Development and in Commercial. Stephanie conducted the research for her PhD in biochemistry in the lab of a Nobel Prize winner at Harvard Medical School and obtained an MPA from the Harvard Kennedy School. As a semi-professional violinist, she performs with Philharmonic orchestras in Carnegie Hall and other international venues and conducts workshops with live orchestras, demonstrating the similarities between teams and leadership in music and management.

Meriem Sefta, PhD, Chief Diagnostics Officer at Owkin

A graduate of Ecole Polytechnique and MIT, Meriem completed her PhD in Cancer Biology at Curie Institute while teaching mathematics and statistical analysis at Paris-Sud University. She was a Research Project Manager before becoming a consultant at AEC Partners. Before her role as Chief Diagnostics Officer, she was Head of Partnerships and head of the Data and Clinical Solutions business unit at Owkin.

Xiaoying Wu, MD, Interim Chief Data Science Officer and Vice President, Data Solutions, Privacy, & Ethics for Innovative Medicine R&D at Johnson & Johnson

Dr. Wu has over 20 years of diverse experience across medical science, data science, medical informatics, and information technology. In her VP role, she spearheaded the development of a bespoke data platform and ecosystem for J&J Innovative Medicine, Med.ai, which integrates and links AI-ready preclinical, clinical trials, and real-world resources to help accelerate the drug discovery and development process, creating opportunities to accelerate data science-driven innovation across the company’s industry-leading R&D portfolio. Xiaoying’s previous role as the leader of RWE CoE & Medical Informatics, Innovative Medicine Commercial Data Science Technology team was marked by the establishment of an enterprise-wide real-world data (RWD) and analytics platform, rHEALTH, which enabled J&J’s leadership in demonstrating the real-world value of our products for patients and health systems. Furthermore, she led the team delivering innovative solutions supporting the Global Commercial Strategy Organization, including early disease identification, predictive HCP targeting, augmented payer/provider strategies, patient data anonymization and re-identification risk assessment. Throughout her professional journey, Xiaoying has made significant contributions to the field. Her work in molecular profiling, advanced analytics, and visualization across several Therapeutic Areas has been instrumental. She has identified predictive biomarkers for patient stratification and conceptualized and executed computational frameworks for pinpointing pharmacodynamic (PD) and pharmacokinetic (K) biomarkers and genomic signatures. These efforts have enhanced scientific understanding of diseases and drug mechanisms of action. With 30+ peer-reviewed publications, Dr. Wu holds an MD from XiangYa School of Medicine, as well as Master of Science degrees in Computer Sciences and Biostatistics from Drexel University and the University of Pennsylvania, respectively.

Diane Wuest, PhD, Vice President of AI & Analytics Products at Genmab, Moderator

Diane is a passionate global executive leading AI programs and digital transformation at the interface of healthcare and technology. She has built deep knowledge in biopharma and high-tech over the past 20 years to accelerate operations and deploy emergent solutions of data and digital to solve healthcare’s most difficult challenges. Diane has designed and implemented technology strategies across AI/ML, data, operations, and digital health to optimize business investments, enterprise platform capabilities, operating models, and resourcing. Currently the VP of AI & Analytics Products at Genmab, she professionalizes AI approaches into stable products and capabilities deployed within all business functions to optimize Genmab’s promise for patients. Prior to Genmab, Diane was VP of Digital R&D at Sanofi, reporting to the Chief Digital Officer, and partnered with the R&D Global Function, where she led the strategic digital transformation of R&D’s engine via technology innovation to accelerate operations and disrupt the way drugs are discovered and developed. Diane also led precision medicine programs at Aitia, a mid-size machine learning startup, where she led strategy and deployed causal inference ML/AI programs with pharma, disease foundations, providers, and technology companies to elucidate disease mechanisms, advance drug discovery and clinical development, and improve patient care. At the start of her career, Diane worked for Genentech in R&D, and her graduate work focused on building a model system of Alzheimer’s disease. Diane received her BS and PhD in chemical & biomolecular engineering from Cornell University and the University of Delaware, respectively.

Pricing Information

• Members: Free
• Non-Members*: $10

*Not a Member? Click here to learn about the benefits of a WIB Membership — access to our video library, mentorship groups, and more. 

Please read WIB's Code of Conduct and Refund Policy

Note: The Zoom meeting link will be sent along with a confirmation email after registration has been completed. 

Special Pricing for Guests

Members can register guests at member pricing.